Sequential FIB-4-based testing limits detection of fibrotic MASLD despite optimized ELF thresholds
In brief
Concurrent FIB-4 and ELF testing catches 87% of fibrotic MASLD
In 186 adults at risk for metabolic liver disease, using FIB-4 at least 1.3 alone missed 43% of patients with fibrosis stage at least 2. Adding ELF with a cutoff of 9.4 as a parallel first-line test raised detection to 87% while keeping specificity around 64%. The findings suggest that simultaneous testing, rather than a stepwise gatekeeper, may better identify patients who need further evaluation.
- Journal
- Hepatology communications (Q1)
- Published
- 7 August 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Alina M Allen, Olivia J Bobek, Rachel E Canning, Maysa Eslami, Joanne Benson, Rondell Graham, et al.
- PMID
- 42566274
- DOI
- 10.1097/HC9.0000000000001012
Why clinicians should know about it
- Picked for Hepatology (top studies of the week, 9 August 2026).
- Picked for Histology (top studies of the week, 9 August 2026).
Abstract
BACKGROUND: Societal guidance recommends sequential noninvasive testing for metabolic dysfunction-associated steatotic liver disease (MASLD), using Fibrosis-4 (FIB-4) ≥1.3 as a gatekeeper before second-line assessment with the Enhanced Liver Fibrosis (ELF) score (<7.7 as a rule-out). The impact of this pathway design on the detection of fibrotic MASH remains uncertain. We aimed to evaluate the performance of guideline-endorsed sequential testing and to determine optimized ELF thresholds within alternative strategies. METHODS: In this prospective study, patients with or at risk for MASLD underwent FIB-4, ELF testing, magnetic resonance elastography (MRE), and liver biopsy within 1 month. Fibrotic MASLD was defined as fibrosis stage ≥2 on histology or liver stiffness ≥3.1 kPa on MRE. Diagnostic performance of ELF was assessed, and sequential (ELF applied after FIB-4 ≥1.3) and concurrent (either test positive) testing strategies were compared.Results:Among 186 participants (median age 51 years; 69% women), fibrotic MASLD was present in 71 (38%). ELF demonstrated AUROC 0.77 (95% CI 0.70-0.84); the cohort-derived cutoff was 9.4 (80% sensitivity, 65% specificity). Lower cutoffs (8.7 and 7.7) increased sensitivity (≥90% and 100%) but low specificity (34% and 4%). FIB-4 ≥1.3 showed limited sensitivity (57%), resulting in 43% of fibrotic MASH cases being excluded from second-line testing. Sequential application of ELF, therefore, failed to overcome this sensitivity ceiling. A concurrent strategy using FIB-4 ≥1.3 or ELF ≥9.4 improved sensitivity to 87% with 64% specificity. CONCLUSIONS: Sequential FIB-4-based testing substantially limits the detection of fibrotic MASLD due to gatekeeping sensitivity constraints. Concurrent first-line testing with FIB-4 and ELF improves case identification, underscoring the importance of pathway design in optimizing noninvasive fibrosis assessment.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.